WO2023176896A1 - Médicament thérapeutique pour infection fongique et méthode de traitement d'une infection fongique - Google Patents
Médicament thérapeutique pour infection fongique et méthode de traitement d'une infection fongique Download PDFInfo
- Publication number
- WO2023176896A1 WO2023176896A1 PCT/JP2023/010134 JP2023010134W WO2023176896A1 WO 2023176896 A1 WO2023176896 A1 WO 2023176896A1 JP 2023010134 W JP2023010134 W JP 2023010134W WO 2023176896 A1 WO2023176896 A1 WO 2023176896A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cells
- human
- fungal infections
- filamentous fungal
- γδt cells
- Prior art date
Links
- 206010017533 Fungal infection Diseases 0.000 title claims abstract description 49
- 208000031888 Mycoses Diseases 0.000 title claims abstract description 48
- 229940126585 therapeutic drug Drugs 0.000 title claims abstract description 7
- 238000000034 method Methods 0.000 title claims description 19
- 239000003814 drug Substances 0.000 claims abstract description 28
- 229940124597 therapeutic agent Drugs 0.000 claims abstract description 15
- 229940079593 drug Drugs 0.000 claims abstract description 11
- 239000004480 active ingredient Substances 0.000 claims abstract description 5
- 210000004027 cell Anatomy 0.000 claims description 74
- 238000011282 treatment Methods 0.000 claims description 17
- 206010061598 Immunodeficiency Diseases 0.000 claims description 11
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 10
- 208000029462 Immunodeficiency disease Diseases 0.000 claims description 7
- 230000007813 immunodeficiency Effects 0.000 claims description 7
- 230000036039 immunity Effects 0.000 claims description 6
- 230000001413 cellular effect Effects 0.000 claims description 5
- 230000003247 decreasing effect Effects 0.000 claims description 5
- 230000001404 mediated effect Effects 0.000 claims description 4
- 208000016683 Adult T-cell leukemia/lymphoma Diseases 0.000 claims description 3
- 201000006966 adult T-cell leukemia Diseases 0.000 claims description 3
- 206010059866 Drug resistance Diseases 0.000 abstract description 3
- 206010067482 No adverse event Diseases 0.000 abstract 1
- 210000000822 natural killer cell Anatomy 0.000 description 40
- 102000000588 Interleukin-2 Human genes 0.000 description 17
- 108010002350 Interleukin-2 Proteins 0.000 description 17
- 241001225321 Aspergillus fumigatus Species 0.000 description 13
- 241000233866 Fungi Species 0.000 description 12
- 230000000843 anti-fungal effect Effects 0.000 description 12
- 108010074328 Interferon-gamma Proteins 0.000 description 9
- 210000005259 peripheral blood Anatomy 0.000 description 9
- 239000011886 peripheral blood Substances 0.000 description 9
- 102100037850 Interferon gamma Human genes 0.000 description 8
- 229940121375 antifungal agent Drugs 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 7
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 230000007246 mechanism Effects 0.000 description 6
- 241000228212 Aspergillus Species 0.000 description 5
- 210000000987 immune system Anatomy 0.000 description 5
- 230000035755 proliferation Effects 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 201000002909 Aspergillosis Diseases 0.000 description 4
- 208000036641 Aspergillus infections Diseases 0.000 description 4
- 206010061418 Zygomycosis Diseases 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 210000005006 adaptive immune system Anatomy 0.000 description 4
- 229940091771 aspergillus fumigatus Drugs 0.000 description 4
- 210000004748 cultured cell Anatomy 0.000 description 4
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 201000007524 mucormycosis Diseases 0.000 description 4
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 229940002612 prodrug Drugs 0.000 description 4
- 239000000651 prodrug Substances 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 108091008874 T cell receptors Proteins 0.000 description 3
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 239000012636 effector Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000002538 fungal effect Effects 0.000 description 3
- 238000009169 immunotherapy Methods 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 210000005007 innate immune system Anatomy 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 2
- 229940122361 Bisphosphonate Drugs 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- 208000009329 Graft vs Host Disease Diseases 0.000 description 2
- 206010062016 Immunosuppression Diseases 0.000 description 2
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 206010057249 Phagocytosis Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 2
- 229960003942 amphotericin b Drugs 0.000 description 2
- 238000003501 co-culture Methods 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 210000000613 ear canal Anatomy 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 208000024908 graft versus host disease Diseases 0.000 description 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 230000001506 immunosuppresive effect Effects 0.000 description 2
- 239000003018 immunosuppressive agent Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 201000009085 invasive aspergillosis Diseases 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 208000004235 neutropenia Diseases 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000008782 phagocytosis Effects 0.000 description 2
- 238000010837 poor prognosis Methods 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000000284 resting effect Effects 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 description 1
- 241000308822 Aspergillus fumigatus Af293 Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010006473 Bronchopulmonary aspergillosis Diseases 0.000 description 1
- 210000003359 CD4-positive helper T lymphocyte Anatomy 0.000 description 1
- 210000001239 CD8-positive, alpha-beta cytotoxic T lymphocyte Anatomy 0.000 description 1
- 108010020326 Caspofungin Proteins 0.000 description 1
- 206010007918 Cellulitis orbital Diseases 0.000 description 1
- 102100025621 Cytochrome b-245 heavy chain Human genes 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 108050001049 Extracellular proteins Proteins 0.000 description 1
- 102100021186 Granulysin Human genes 0.000 description 1
- 101710168479 Granulysin Proteins 0.000 description 1
- 102000001398 Granzyme Human genes 0.000 description 1
- 108060005986 Granzyme Proteins 0.000 description 1
- 101710182268 Heat shock protein HSP 90 Proteins 0.000 description 1
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 208000037026 Invasive Fungal Infections Diseases 0.000 description 1
- 206010023379 Ketoacidosis Diseases 0.000 description 1
- 208000007976 Ketosis Diseases 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 108010021062 Micafungin Proteins 0.000 description 1
- 241000235395 Mucor Species 0.000 description 1
- 241000235388 Mucorales Species 0.000 description 1
- UBQYURCVBFRUQT-UHFFFAOYSA-N N-benzoyl-Ferrioxamine B Chemical compound CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN UBQYURCVBFRUQT-UHFFFAOYSA-N 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 206010029155 Nephropathy toxic Diseases 0.000 description 1
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 1
- 208000001388 Opportunistic Infections Diseases 0.000 description 1
- 208000000493 Orbital Cellulitis Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 102000004503 Perforin Human genes 0.000 description 1
- 108010056995 Perforin Proteins 0.000 description 1
- KHGNFPUMBJSZSM-UHFFFAOYSA-N Perforine Natural products COC1=C2CCC(O)C(CCC(C)(C)O)(OC)C2=NC2=C1C=CO2 KHGNFPUMBJSZSM-UHFFFAOYSA-N 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 208000004430 Pulmonary Aspergillosis Diseases 0.000 description 1
- 206010037422 Pulmonary mycosis Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 241000235402 Rhizomucor Species 0.000 description 1
- 241000235527 Rhizopus Species 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 238000011256 aggressive treatment Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- -1 alkenyl amine Chemical class 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 150000004663 bisphosphonates Chemical class 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 238000010322 bone marrow transplantation Methods 0.000 description 1
- 201000009267 bronchiectasis Diseases 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- JYIKNQVWKBUSNH-WVDDFWQHSA-N caspofungin Chemical compound C1([C@H](O)[C@@H](O)[C@H]2C(=O)N[C@H](C(=O)N3CC[C@H](O)[C@H]3C(=O)N[C@H](NCCN)[C@H](O)C[C@@H](C(N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)N2)[C@@H](C)O)=O)NC(=O)CCCCCCCC[C@@H](C)C[C@@H](C)CC)[C@H](O)CCN)=CC=C(O)C=C1 JYIKNQVWKBUSNH-WVDDFWQHSA-N 0.000 description 1
- 229960003034 caspofungin Drugs 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- OEUUFNIKLCFNLN-LLVKDONJSA-N chembl432481 Chemical compound OC(=O)[C@@]1(C)CSC(C=2C(=CC(O)=CC=2)O)=N1 OEUUFNIKLCFNLN-LLVKDONJSA-N 0.000 description 1
- 208000016532 chronic granulomatous disease Diseases 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000000254 damaging effect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 229960000958 deferoxamine Drugs 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 208000001936 exophthalmos Diseases 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 208000024386 fungal infectious disease Diseases 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 238000011134 hematopoietic stem cell transplantation Methods 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 208000021760 high fever Diseases 0.000 description 1
- 230000007236 host immunity Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 239000012642 immune effector Substances 0.000 description 1
- 230000006058 immune tolerance Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 230000006054 immunological memory Effects 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 229940124589 immunosuppressive drug Drugs 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229960004130 itraconazole Drugs 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 229960002159 micafungin Drugs 0.000 description 1
- PIEUQSKUWLMALL-YABMTYFHSA-N micafungin Chemical compound C1=CC(OCCCCC)=CC=C1C1=CC(C=2C=CC(=CC=2)C(=O)N[C@@H]2C(N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)N3C[C@H](C)[C@H](O)[C@H]3C(=O)N[C@H](O)[C@H](O)C2)[C@H](O)CC(N)=O)[C@H](O)[C@@H](O)C=2C=C(OS(O)(=O)=O)C(O)=CC=2)[C@@H](C)O)=O)=NO1 PIEUQSKUWLMALL-YABMTYFHSA-N 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 208000013435 necrotic lesion Diseases 0.000 description 1
- 230000007694 nephrotoxicity Effects 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- 208000020470 nervous system symptom Diseases 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000003254 palate Anatomy 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 229930192851 perforin Natural products 0.000 description 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 201000009890 sinusitis Diseases 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000011301 standard therapy Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 229960004740 voriconazole Drugs 0.000 description 1
- BCEHBSKCWLPMDN-MGPLVRAMSA-N voriconazole Chemical compound C1([C@H](C)[C@](O)(CN2N=CN=C2)C=2C(=CC(F)=CC=2)F)=NC=NC=C1F BCEHBSKCWLPMDN-MGPLVRAMSA-N 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- XRASPMIURGNCCH-UHFFFAOYSA-N zoledronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CN1C=CN=C1 XRASPMIURGNCCH-UHFFFAOYSA-N 0.000 description 1
- 229960004276 zoledronic acid Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
Definitions
- the present invention relates to a therapeutic agent for filamentous fungal infections and a method for treating filamentous fungal infections.
- Filamentous fungal infections such as aspergillosis and mucormycosis, are diseases with a poor prognosis that are often seen in patients with weakened immune systems, and the standard therapy is the administration of low-molecular antifungal drugs, but cases with a poor prognosis There are many. Furthermore, in recent years, the number of filamentous fungi that are resistant to low-molecular-weight antifungal drugs has been on the rise. In addition, since the proteins that serve as drug discovery targets for filamentous fungi are structurally similar to proteins derived from human cells, it is extremely difficult to develop low-molecular-weight drugs that specifically act against filamentous fungi, resulting in nephrotoxicity. Side effects such as these are also notable. In fact, only one first-in-class drug has been marketed in the past 30 years. Therefore, it is essential to develop new drug modalities different from small molecules.
- Non-Patent Document 1 describes as follows. NK cells whose proliferation is induced using IL-2 or the like exhibit toxicity to tumor cells and cells infected with pathogenic microorganisms. Therefore, it is possible to develop therapeutic methods for fungal infections by utilizing the immune effector action or killing action of IL-2-induced NK cells. Specifically, it is possible to treat filamentous fungal infections by injecting IL-2-induced NK cells as adoptive immunotherapy into patients who have become susceptible to infection due to immunosuppressants during hematopoietic stem cell transplantation. There is. However, this literature does not explain how IL-2-induced NK cells control invasive fungal infections caused by fungi such as Aspergillus in patients receiving hematopoietic stem cell infusion therapy.
- NK cells activate innate immune system cells derived from hematopoietic stem cells and their own innate immune system cells, increasing fungal phagocytosis. It is thought that it may enhance sterilization and bactericidal ability, but no scientific evidence has been shown for this. In addition, it is thought that NK cells activate B cells, which are cells of the adaptive immune system, and enhance their antibody production ability, increasing antibody-dependent cytotoxicity and cell phagocytosis, but there is no scientific evidence for this. Nor.
- NK cells enhance the activation of Th1 type CD4-positive helper T cells, which are cells of the adaptive immune system, and enhance the ability to produce cytokines such as interferon- ⁇ (IFN- ⁇ ) and IL-2. It is thought that this may enhance the antifungal activity of the entire immune system, but there is no scientific evidence for this.
- NK cells enhance the activation of CD8-positive killer T cells, which are cells of the adaptive immune system, and enhance their ability to produce cytokines such as IFN- ⁇ and tumor necrosis factor- ⁇ (TNF- ⁇ ). , it is also possible that it induces antifungal effects, but no scientific evidence has been shown for this. As described above, there are many unknown points regarding the treatment of filamentous fungal infections using IL-2-induced NK cells.
- Non-Patent Document 2 describes as follows. The mechanism of immune action mediated by IL-2-induced NK cells against malignant tumors and viruses has been clarified, but IL-2 and filamentous fungi, especially Aspergillus fungi, which are the main cause of invasive aspergillosis. There is little knowledge regarding the -2-induced interaction with NK cells. Therefore, we investigated how NK cells exhibit antifungal effects. First, we investigated the in vitro interaction between human NK cells and Aspergillus fumigatus, and found that only germinated bacterial cells showed high immunogenicity and were able to induce Th1-like responses, including IFN- ⁇ , TNF- ⁇ , etc. It has been shown that this enhances the production of cytokines.
- NK cells when NK cells were primed with human recombinant IL-2 and brought into direct contact with the pathogen, NK cells showed toxicity against A. fumigatus.
- the most interesting finding is that NK cells are A. When exhibiting a bactericidal effect on S. fumigutus cells, they did not degranulate and release the cytotoxic proteins perforin, granzyme, and granulysin, but through an alternative mechanism using another soluble factor. However, the mechanism is not completely clear.
- IFN- ⁇ released by NK cells directly damages A. fumigatus, suggesting that human NK cells and IFN- ⁇ may serve as a new therapeutic tool against fungal infections. .
- IFN- ⁇ acts on the IFN- ⁇ receptor on human cells and exhibits effector action, it is unlikely that such a receptor exists in filamentous fungi. There are many unknowns regarding the details, such as whether it directly acts on filamentous fungi.
- Non-Patent Document 3 describes as follows. Natural killer (NK) cells exhibit antifungal activity against A. fumigatus and, as a result, can enhance the host's defense function. However, little is known regarding the mechanism of interaction between NK cells and A. fumigatus. In this paper, human NK cells and A. fumigatus hyphae are brought into contact and gene expression and protein concentration of specific molecules are evaluated. The results revealed that when NK cells were exposed to A. fumigatus, the transcription and translation of inflammatory protein molecules within the NK cells was increased. However, the post-translational release of inflammatory proteins from NK cells was suppressed by some mechanism, and these molecules accumulated within NK cells and did not act outside the cells. On the other hand, A.
- A. fumigatus acted on NK cells and decreased the mRNA level of perforin, but on the contrary, increased its intracellular and extracellular protein concentrations.
- A. fumigatus also increased gene expression of stress-related molecules such as the heat shock protein HSP90 in human NK cells.
- NK cells are cells that account for approximately 5% to 30% of mononuclear cells present in human peripheral blood, and are characterized by CD56 (+) and CD3 (-).
- the name NK derives from the fact that it exhibits toxicity to tumor cells and virus-infected cells both in vivo and in vitro without prior stimulation.
- NK cells In addition to acting as pure innate immune system cells, NK cells have also been reported to have properties similar to adaptive immune system cells, such as immunological memory, and have been shown to act as host immune cells against various pathogens ( Mainly responsible for antiviral action). Based on previous knowledge, it is predicted that when NK cells are used as a cell preparation for antifungal therapy, the effect will be low unless the effector/target ratio is large.
- NK cells 1 ⁇ 10 9 to 1 ⁇ 10 10 or more NK cells are required for one treatment.
- the conventional proliferation method using IL-2 as an activator it is difficult to prepare 1 ⁇ 10 9 to 1 ⁇ 10 10 or more NK cells.
- methods for proliferating NK cells using genetically modified K562 cells and the like as feeder cells have been devised, a method for preparing NK cells that is compatible with Good Gene, Cellular, and Tissue-based Products Manufacturing Practice (GCTP) has not been established. Therefore, at present, it is extremely difficult to efficiently prepare NK cells as a cell preparation for antifungal therapy.
- GCTP Good Gene, Cellular, and Tissue-based Products Manufacturing Practice
- An object of the present invention is to provide a therapeutic agent for filamentous fungal infections and a method for treating filamentous fungal infections, which have no side effects and are less susceptible to drug resistance.
- the present invention includes the following aspects.
- the therapeutic agent for filamentous fungal infections according to [2], wherein the patient with decreased immunity is a patient with cellular immunodeficiency.
- the drug for treating filamentous fungal infections according to [3], wherein the cellular immunodeficiency patient is an adult T-cell leukemia/lymphoma patient.
- [6] Use of human ⁇ T cells for producing a therapeutic agent for filamentous fungal infections. [7] The use according to [6], wherein the human ⁇ T cells are cultured human ⁇ T cells. [8] Human ⁇ T cells for use in the treatment of fungal infections. [9] Cultured human ⁇ T cells for use in the treatment of fungal infections. [10] A method for treating a filamentous fungal infection, comprising administering a therapeutically effective amount of human ⁇ T cells to a patient in need of treatment.
- the present invention it is possible to provide a therapeutic drug for filamentous fungal infections and a method for treating filamentous fungal infections, which have no side effects and are less susceptible to drug resistance.
- FIG. 1 is a graph showing the purity and number of ⁇ T cells in the peripheral blood of a healthy person before culture and after 10 days of culture.
- FIG. 2 is a graph showing the results of co-culture of Af293 and ⁇ T cells.
- the filamentous fungal infection is a human filamentous fungal infection.
- the fungal infections to be treated by the present invention are particularly deep-seated fungal infections, such as aspergillosis and mucormycosis.
- Aspergillosis is an opportunistic infection caused by inhaling the spores of Aspergillus, a filamentous fungus that is ubiquitous in the environment. The spores germinate, grow, become hyphae, enter blood vessels, and become invasive. The disease causes hemorrhagic necrosis and infarction. They may present with symptoms of asthma, pneumonia, sinusitis, or rapidly progressive systemic disease. Diagnosis is mainly made clinically, but image tests, histopathological tests, and specimen staining and culture may be helpful. Treatment is with voriconazole, amphotericin B (or its lipid formulation), caspofungin, micafungin, or itraconazole. Fungal balls may require surgical removal.
- Major risk factors for aspergillosis include long-term neutropenia (typically >7 days), long-term high-dose steroid therapy, and organ transplantation (particularly bone marrow transplantation with graft-versus-host disease [GVHD]). , and genetic disorders related to neutrophil function (eg, chronic granulomatous disease). Aspergillus fungi tend to infect open spaces such as lung cavities, sinuses, and ear canals (e.g., ear canal mycosis) caused by previous lung disease (eg, bronchiectasis, tumors, tuberculosis).
- Mucormycosis refers to infectious diseases caused by various fungal species belonging to the order Mucorales, such as the genera Rhizopus, Rhizomucor, and Mucor. Symptoms most frequently result from aggressive necrotic lesions of the nose and palate, resulting in pain, fever, orbital cellulitis, proptosis, and purulent nasal discharge. This may be followed by central nervous system symptoms. Pulmonary symptoms are severe and include a productive cough, high fever, and difficulty breathing. Disseminated infection may occur in severely immunocompromised patients. Diagnosis is mainly made clinically, but it is necessary to strongly suspect this condition, and it is confirmed by histopathological examination and culture. Treatment consists of intravenous amphotericin B and surgery to remove necrotic tissue. Despite aggressive treatment, mortality is high. Mucormycosis is most common in immunocompromised individuals, patients with poorly controlled diabetes (particularly those with ketoacidosis), and patients receiving the iron chelator deferoxamine.
- One embodiment of the present invention is a therapeutic agent for filamentous fungal infections containing human ⁇ T cells as the main active ingredient.
- Human ⁇ T cells which are the active ingredients of the therapeutic agent of this embodiment, are ⁇ T cells isolated from human peripheral blood or cultured cells thereof. Human ⁇ T cells may be autologous or allogeneic. In other words, as human ⁇ T cells, both ⁇ T cells and cultured cells thereof isolated from a subject to whom the therapeutic drug is administered, as well as ⁇ T cells and cultured cells thereof isolated from a donor other than the subject to whom the therapeutic drug is administered, may be used. I can do it.
- Human ⁇ T cells have the following characteristics. ⁇ Accounts for 1-5% of T cells in peripheral blood. -Characterized by CD4 (-), CD8 (-) (some ⁇ T cells express CD8 ⁇ chain dimer and therefore become weakly positive for CD8), and CD3 (+). - Expresses the T cell receptor (TCR), which is composed of ⁇ and ⁇ chains. -Unlike human ⁇ T cells, they are not restricted by major histocompatibility complex (MHC). - As described below, ex vivo expansion culture is possible using human peripheral blood (proliferation/activation by recognition of phosphoantigen). ⁇ The results of a phase II study in the field of human solid tumors confirmed that there are no major safety concerns.
- MHC major histocompatibility complex
- human ⁇ T cells expressing a V ⁇ 9V ⁇ 2-positive T cell receptor (there are two nomenclatures for V ⁇ , so V ⁇ 9 is also written as V ⁇ 2) are preferred.
- the culture method is not particularly limited, but the nitrogen-containing bisphosphonic acid prodrug tetrakis-pivaloyloxymethyl 2-(thiazole-2-
- a method of producing highly enriched human ⁇ T cells using ylamino)ethylidene-1,1-bisphosphonate (PTA) and IL-2 is preferred.
- PTA ylaminoethylidene-1,1-bisphosphonate
- IL-18 it is also possible to enhance the proliferation of ⁇ T cells by adding IL-18 or mutant IL-18 to the expansion culture system.
- a specific cell proliferation method for example, Tanaka et al. Vol., No. 3, p.587-599), Okuno et al.
- peripheral blood ⁇ T cells can be efficiently proliferated to about 500 to 10,000 times the number of cells with a purity of 90% to 99% or more in 8 to 11 days of culture.
- one or more of pyrophosphate monoester, phosphoric acid monoester, nitrogen-containing bisphosphonic acid, nitrogen-containing bisphosphonic acid prodrug, alkyl amine, or alkenyl amine is selected instead of PTA, and IL-2 or A combination of one or more of IL-15, IL-18, or their mutants having equivalent effects may be added and cultured.
- IL-2 variants are disclosed in US 2014/0046026 A1
- IL-18 variants are disclosed in EP 0 692 536 A2, EP 0 712 931 A2, EP 0 767 178 A1, and WO 1997/002441 A1, etc.
- it is disclosed in WO 2022/172944 A1 (PCT/JP2022/005051), but is not limited thereto.
- the subject to whom the therapeutic agent of this embodiment is administered is not particularly limited as long as it is a patient who has developed a filamentous fungal infection, but patients with weakened immunity are preferred.
- the patient with decreased immunity is preferably a patient with cellular immunodeficiency.
- the cell-mediated immunodeficiency patient is preferably an adult T-cell leukemia/lymphoma patient.
- the method for administering the therapeutic agent of this embodiment is not particularly limited, but it is preferable to intravenously infuse a cell suspension containing human ⁇ T cells. Although the detailed mechanism of intravenously infused ⁇ T cells is unknown, they tend to accumulate in the lungs and are particularly effective against pulmonary mycosis such as pulmonary aspergillosis.
- Mechanism of action The mechanism of action of the therapeutic agent of this embodiment is not particularly limited, but it is thought to be due to direct damaging activity due to contact between ⁇ T cells and hyphae of filamentous fungi.
- Human ⁇ T cells to produce a therapeutic drug for fungal infections
- Another embodiment of the invention is the use of human ⁇ T cells to produce a medicament for the treatment of fungal infections.
- Human ⁇ T cells are as described above.
- Human ⁇ T cells for use in the treatment of fungal infections Yet another embodiment of the invention is human ⁇ T cells for use in treating fungal infections.
- Human ⁇ T cells are as described above.
- Yet another embodiment of the invention is a method of treating a fungal infection comprising administering a therapeutically effective amount of human ⁇ T cells to a patient in need of treatment.
- Human ⁇ T cells are as described above.
- the therapeutically effective amount of human ⁇ T cells is not particularly limited, but is preferably 10 3 to 10 12 cells per infusion.
- V ⁇ 9V ⁇ 2-positive ⁇ T cells Peripheral blood V ⁇ 9V ⁇ 2-positive ⁇ T cells from healthy individuals or patients infected with filamentous fungi were induced to proliferate/activated ex vivo in the presence of PTA and IL-2 by the method described above (Tanaka et al. (2017)).
- Aspergillus fumigatus Af293 wild strain provided by the filamentous fungus American Type Culture Collection (ATCC).
- FIG. 1 shows the purity and number of ⁇ T cells in the peripheral blood of healthy subjects before culture and 10 days after culture.
- Figure 2 shows the results of co-culture of Af293 and ⁇ T cells. A bactericidal effect on Af293 of V ⁇ 9V ⁇ 2 T cells was observed.
- the advantage of the present invention is that cell medicine is developed as a new pharmaceutical modality for treating filamentous fungal infections. Specifically, human peripheral blood mononuclear cells are purified, stimulated with the nitrogen-containing bisphosphonic acid prodrug PTA, and IL-2 is added to expand and culture V ⁇ 9V ⁇ 2-positive ⁇ T cells for use. This disease occurs in patients with immunodeficiency, and the concept of activating the immune system is very logical and is thought to have a therapeutic effect that cannot be expected with antifungal drugs. Not affected.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Cell Biology (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
L'invention concerne un médicament thérapeutique destiné à une infection fongique, le médicament contenant des cellules γδT humaines en tant que principe actif. L'agent thérapeutique pour infection fongique ne présente pas d'effets indésirables et tend à ne pas être affecté par la pharmacorésistance.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2022-043792 | 2022-03-18 | ||
JP2022043792 | 2022-03-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2023176896A1 true WO2023176896A1 (fr) | 2023-09-21 |
Family
ID=88023892
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2023/010134 WO2023176896A1 (fr) | 2022-03-18 | 2023-03-15 | Médicament thérapeutique pour infection fongique et méthode de traitement d'une infection fongique |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2023176896A1 (fr) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006500373A (ja) * | 2002-08-26 | 2006-01-05 | ランバクシー ラボラトリーズ リミテッド | 抗真菌剤としてのアゾール誘導体 |
WO2007020936A1 (fr) * | 2005-08-17 | 2007-02-22 | Daiichi Sankyo Company, Limited | Composé bicyclique hétérocyclique possédant une action fongicide |
JP2010540522A (ja) * | 2007-09-28 | 2010-12-24 | メルク シャープ アンド ドーム コープ. | 抗真菌剤 |
JP2016501013A (ja) * | 2012-11-08 | 2016-01-18 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | γδT細胞の無IL−2増殖を誘導するための方法 |
JP2018533373A (ja) * | 2015-10-30 | 2018-11-15 | キャンサー・リサーチ・テクノロジー・リミテッド | 非造血組織常在性γδ T細胞の増幅および該細胞の使用 |
-
2023
- 2023-03-15 WO PCT/JP2023/010134 patent/WO2023176896A1/fr active Search and Examination
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006500373A (ja) * | 2002-08-26 | 2006-01-05 | ランバクシー ラボラトリーズ リミテッド | 抗真菌剤としてのアゾール誘導体 |
WO2007020936A1 (fr) * | 2005-08-17 | 2007-02-22 | Daiichi Sankyo Company, Limited | Composé bicyclique hétérocyclique possédant une action fongicide |
JP2010540522A (ja) * | 2007-09-28 | 2010-12-24 | メルク シャープ アンド ドーム コープ. | 抗真菌剤 |
JP2016501013A (ja) * | 2012-11-08 | 2016-01-18 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | γδT細胞の無IL−2増殖を誘導するための方法 |
JP2018533373A (ja) * | 2015-10-30 | 2018-11-15 | キャンサー・リサーチ・テクノロジー・リミテッド | 非造血組織常在性γδ T細胞の増幅および該細胞の使用 |
Non-Patent Citations (3)
Title |
---|
AMARSAIKHAN NANSALMAA; O'DEA EVAN M.; TSOGGEREL ANGAR; TEMPLETON STEVEN P.: "Lung eosinophil recruitment in response toAspergillus fumigatusis correlated with fungal cell wall composition and requires γδ T cells", MICROBES AND INFECTION, ELSEVIER, PARIS, FR, vol. 19, no. 7, 2017, FR , pages 422 - 431, XP085130492, ISSN: 1286-4579, DOI: 10.1016/j.micinf.2017.05.001 * |
H. HEBART: "Analysis of T-cell responses to Aspergillus fumigatus antigens in healthy individuals and patients with hematologic malignancies", BLOOD, vol. 100, no. 13, 15 December 2002 (2002-12-15), pages 4521 - 4528, XP055169964, ISSN: 00064971, DOI: 10.1182/blood-2002-01-0265 * |
REEDER KRISTEN M, MACKEL JOSEPH J, GODWIN MATTHEW S, DUNAWAY CHAD W, BLACKBURN JONATHAN P, PATEL RAKESH P, STEELE CHAD: "Role of Common γ-Chain Cytokines in Lung Interleukin-22 Regulation after Acute Exposure to Aspergillus fumigatus", INFECTION AND IMMUNITY, AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 86, no. 10, 1 October 2018 (2018-10-01), US , pages 1 - 14, XP093091013, ISSN: 0019-9567, DOI: 10.1128/IAI.00157-18 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Jasani et al. | Ampligen: a potential toll-like 3 receptor adjuvant for immunotherapy of cancer | |
JP5524056B2 (ja) | CTLとγδT細胞の同時誘導方法 | |
Chang et al. | Combined GM‐CSF and IL‐12 gene therapy synergistically suppresses the growth of orthotopic liver tumors | |
AU693459B2 (en) | A method for sensitization of cancer cells for killer cell mediated lysis | |
Panagioti et al. | Immunostimulatory bacterial antigen–armed oncolytic measles virotherapy significantly increases the potency of anti-PD1 checkpoint therapy | |
US10946080B2 (en) | Compositions and methods for combination therapy with dengue virus and dendritic cells | |
KR20140117244A (ko) | 조절 t 세포로의 분화 유도 및 증식 촉진을 통한 면역 반응 억제용 약학 조성물 | |
US20060269526A1 (en) | Stromal antigen-presenting cells and use thereof | |
US9855330B2 (en) | Granulysin in immunotherapy | |
González-Juarrero et al. | Optimization of inhaled therapies for tuberculosis: the role of macrophages and dendritic cells | |
US20040120926A1 (en) | Reactive oxygen metabolite inhibitors for use in compositions and methods of treatment | |
KR101620341B1 (ko) | 염증성장질환 및 1형 당뇨병치료를 위한 apl 펩티드의 사용 | |
WO2016163489A1 (fr) | Médicament | |
JPWO2018070069A1 (ja) | 医薬 | |
AU2017224499A1 (en) | Pharmaceutical composition for preventing or treating regulatory T cell-mediated diseases | |
WO2017147894A1 (fr) | Composition améliorant la capacité à tuer des cellules anormales, et utilisation associée | |
WO2023176896A1 (fr) | Médicament thérapeutique pour infection fongique et méthode de traitement d'une infection fongique | |
Okita et al. | Targeting of CD4+ CD25high cells while preserving CD4+ CD25low cells with low-dose chimeric anti-CD25 antibody in adoptive immunotherapy of cancer | |
Park et al. | Doxorubicin enhances CD4+ T-cell immune responses by inducing expression of CD40 ligand and 4-1BB | |
JPWO2008065752A1 (ja) | diRNAを有効成分とする免疫治療用薬剤 | |
JP2022547169A (ja) | 線維芽細胞による外傷性脳症の治療と治療補助薬 | |
WO2021024897A1 (fr) | Médicament combiné pour le traitement d'une tumeur maligne, composition pharmaceutique destinée à traiter une tumeur maligne et composition pharmaceutique pour le traitement de tumeurs malignes | |
JPWO2005011723A1 (ja) | 造血器腫瘍の予防および/または治療剤 | |
WO2023118868A1 (fr) | Bifidobacterium et ses compositions pour le traitement du cancer du sein | |
JPWO2008129874A1 (ja) | 腫瘍細胞の標的化方法、及びその用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23770849 Country of ref document: EP Kind code of ref document: A1 |
|
DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) |